The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Are you searching for medications to treat 'Nasal Polyp'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Nasal Polyp. The page includes both ...

which found that treatment with Fasenra achieved a statistically significant improvement in the endoscopic total nasal polyp score and nasal blockage score compared to placebo, in patients with ...

Fasenra demonstrated a statistically significant improvement in the endoscopic total nasal polyp score and the nasal blockage score compared to placebo, in patients with severe disease who were ...

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

She was referred to the otolaryngology clinic with complaints of chronic nasal stuffiness, usually clear with episodes of purulent rhinorrhea, anosmia, and occasional headaches. Antibiotics were ...

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

GSK receives Japanese MHLW approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Thursday, August 29, 2024, 09:00 Hrs [IST] GSK plc announc ...

When sinusitis does not respond to treatment, your doctor may recommend surgery to remove a polyp or nasal tissue.